Mao Mao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6496921/publications.pdf

Version: 2024-02-01

361296 677027 3,900 24 20 citations h-index papers

g-index 24 24 24 7741 citing authors all docs docs citations times ranked

22

#	Article	IF	CITATIONS
1	Whole-genome sequencing and comprehensive molecular profiling identify new driver mutations in gastric cancer. Nature Genetics, 2014, 46, 573-582.	9.4	895
2	Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nature Genetics, 2012, 44, 765-769.	9.4	785
3	Exome sequencing identifies frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nature Genetics, 2011, 43, 1219-1223.	9.4	662
4	Whole-genome sequencing identifies recurrent mutations in hepatocellular carcinoma. Genome Research, 2013, 23, 1422-1433.	2.4	457
5	Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma. Hepatology, 2013, 58, 706-717.	3.6	159
6	Comprehensive analysis of RET and ROS1 rearrangement in lung adenocarcinoma. Modern Pathology, 2015, 28, 468-479.	2.9	114
7	A Single-Tube Multiplexed Assay for Detecting ALK, ROS1, and RET Fusions in Lung Cancer. Journal of Molecular Diagnostics, 2014, 16, 229-243.	1.2	105
8	HIP1–ALK, A Novel ALK Fusion Variant that Responds to Crizotinib. Journal of Thoracic Oncology, 2014, 9, 285-294.	0.5	84
9	A Novel Fusion of TPR and ALK in Lung Adenocarcinoma. Journal of Thoracic Oncology, 2014, 9, 563-566.	0.5	83
10	Comprehensive Characterization of Oncogenic Drivers in Asian Lung Adenocarcinoma. Journal of Thoracic Oncology, 2016, 11, 2129-2140.	0.5	70
11	Predictive Genes in Adjacent Normal Tissue Are Preferentially Altered by sCNV during Tumorigenesis in Liver Cancer and May Rate Limiting. PLoS ONE, 2011, 6, e20090.	1.1	68
12	Multiplexed Gene Expression and Fusion Transcript Analysis to Detect ALK Fusions in Lung Cancer. Journal of Molecular Diagnostics, 2013, 15, 51-61.	1.2	63
13	Next generation sequencing reveals genetic landscape of hepatocellular carcinomas. Cancer Letters, 2013, 340, 247-253.	3.2	59
14	Patterns of somatic alterations between matched primary and metastatic colorectal tumors characterized by whole-genome sequencing. Genomics, 2014, 104, 234-241.	1.3	58
15	ALK, ROS1 and RET rearrangements in lung squamous cell carcinoma are very rare. Lung Cancer, 2016, 94, 22-27.	0.9	56
16	Decoding complex patterns of genomic rearrangement in hepatocellular carcinoma. Genomics, 2014, 103, 189-203.	1.3	49
17	Clinical characteristics associated with ALK rearrangements in never-smokers with pulmonary adenocarcinoma. Lung Cancer, 2014, 83, 259-264.	0.9	30
18	Test of Four Colon Cancer Risk-Scores in Formalin Fixed Paraffin Embedded Microarray Gene Expression Data. Journal of the National Cancer Institute, 2014, 106, .	3.0	30

#	Article	IF	CITATION
19	<i>SEC31A-ALK</i> Fusion Gene in Lung Adenocarcinoma. Cancer Research and Treatment, 2016, 48, 398-402.	1.3	27
20	Aberrant CDK4 Amplification in Refractory Rhabdomyosarcoma as Identified by Genomic Profiling. Scientific Reports, 2014, 4, 3623.	1.6	25
21	Noninvasive Detection of Hepatocellular Carcinoma with Circulating Tumor DNA FeaturesÂand α-Fetoprotein. Journal of Molecular Diagnostics, 2021, 23, 1174-1184.	1.2	14
22	Distinct mutations and lineages of SARSâ€CoVâ€2 virus in the early phase of COVIDâ€19 pandemic and subsequent 1â€year global expansion. Journal of Medical Virology, 2022, 94, 2035-2049.	2.5	7
23	Detecting <i>ALK</i> fusions in lung cancer: multiple choice testing?. Lung Cancer Management, 2013, 2, 173-175.	1.5	O
24	Whole-genome sequencing as an alternative to analyze copy number abnormalities in acute myeloid leukemia and myelodysplastic syndrome. Leukemia and Lymphoma, 2022, 63, 2301-2310.	0.6	0